CN107922349B - 作为fgfr和vegfr抑制剂的乙烯基化合物 - Google Patents

作为fgfr和vegfr抑制剂的乙烯基化合物 Download PDF

Info

Publication number
CN107922349B
CN107922349B CN201680046188.0A CN201680046188A CN107922349B CN 107922349 B CN107922349 B CN 107922349B CN 201680046188 A CN201680046188 A CN 201680046188A CN 107922349 B CN107922349 B CN 107922349B
Authority
CN
China
Prior art keywords
mmol
lcms
esi
added
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680046188.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922349A (zh
Inventor
陈曙辉
陈正霞
戴美碧
谢程
李鹏
张杨
梁贵柏
王强
廖江鹏
孙飞
胡国平
黎健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Zhenbao Pharmaceutical Co ltd
Original Assignee
Harbin Zhenbao Pharmaceutical Co ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin Zhenbao Pharmaceutical Co ltd, Medshine Discovery Inc filed Critical Harbin Zhenbao Pharmaceutical Co ltd
Publication of CN107922349A publication Critical patent/CN107922349A/zh
Application granted granted Critical
Publication of CN107922349B publication Critical patent/CN107922349B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680046188.0A 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物 Active CN107922349B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510484124 2015-08-07
CN2015104841246 2015-08-07
CN201510908082 2015-12-09
CN2015109080824 2015-12-09
PCT/CN2016/092989 WO2017024968A1 (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Publications (2)

Publication Number Publication Date
CN107922349A CN107922349A (zh) 2018-04-17
CN107922349B true CN107922349B (zh) 2021-05-07

Family

ID=57983012

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680046188.0A Active CN107922349B (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Country Status (5)

Country Link
US (1) US10519133B2 (cg-RX-API-DMAC10.html)
EP (1) EP3333157B1 (cg-RX-API-DMAC10.html)
JP (1) JP6898306B2 (cg-RX-API-DMAC10.html)
CN (1) CN107922349B (cg-RX-API-DMAC10.html)
WO (1) WO2017024968A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6803410B2 (ja) * 2017-02-14 2020-12-23 富士フイルム株式会社 インダゾール化合物の製造方法およびインダゾール化合物
US11078194B2 (en) * 2017-12-07 2021-08-03 Harbin Zhenbao Pharmaceutical Co., Ltd. Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
WO2020135878A1 (zh) * 2018-12-29 2020-07-02 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
MX2021009261A (es) * 2019-02-02 2021-11-12 Shanghai Fosun Pharmaceutical Ind Development Co Ltd Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
KR102668124B1 (ko) * 2019-02-02 2024-05-23 노바온코 제이에스 테라퓨틱스 컴퍼니 리미티드 Pd-l1 면역조절제인 비닐 피리딘 카르복사미드 화합물
WO2020249096A1 (zh) * 2019-06-14 2020-12-17 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
CN114072387B (zh) * 2019-11-06 2024-03-08 暨南大学 吲唑类化合物及其药用组合物和应用
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113666911B (zh) * 2020-08-11 2025-08-26 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
JP2023553835A (ja) * 2020-12-17 2023-12-26 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状化合物およびそれらの使用
MX2023007793A (es) * 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
CN116761798A (zh) * 2020-12-30 2023-09-15 泰拉生物科学公司 作为激酶抑制剂的吲唑类化合物
WO2023279041A1 (en) * 2021-06-30 2023-01-05 Tyra Biosciences, Inc. Indazole compounds
IL317558A (en) * 2022-06-29 2025-02-01 Tyra Biosciences Inc Indazole compounds
CN116239623B (zh) * 2022-11-18 2025-11-18 江西亚太科技发展有限公司 一种硼酸酯的制备方法及其应用
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
US20030207883A1 (en) * 2001-07-03 2003-11-06 Chiron Corporation Indazole benzimidazole compounds
CN1747950A (zh) * 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2-(1h-吲唑-6-基氨基)-苯甲酰胺化合物
US20060058366A1 (en) * 2002-12-03 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
CN102421769A (zh) * 2009-05-07 2012-04-18 伊莱利利公司 乙烯基吲唑基化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
US20030207883A1 (en) * 2001-07-03 2003-11-06 Chiron Corporation Indazole benzimidazole compounds
US20060058366A1 (en) * 2002-12-03 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
CN1747950A (zh) * 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2-(1h-吲唑-6-基氨基)-苯甲酰胺化合物
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
CN102421769A (zh) * 2009-05-07 2012-04-18 伊莱利利公司 乙烯基吲唑基化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors;Stéphanie Blanchard et al.;《Bioorganic & Medicinal Chemistry Letters》;20100307;第20卷;第2445页Table2 *
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase(TTK) Inhibitors:3-(4-(heterocyclyl) phenyl) -1H-indazole-5-carboxamidesas Anticancer Agents;YongLiu et al.;《Journal of Medicinal Chemistry》;20150312;第58卷(第8期);第3370页Table2,第3375页Table5 *

Also Published As

Publication number Publication date
EP3333157A1 (en) 2018-06-13
US10519133B2 (en) 2019-12-31
JP6898306B2 (ja) 2021-07-07
WO2017024968A1 (zh) 2017-02-16
EP3333157A4 (en) 2018-10-17
US20180222886A1 (en) 2018-08-09
CN107922349A (zh) 2018-04-17
JP2018531218A (ja) 2018-10-25
EP3333157B1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
JP6898306B2 (ja) Fgfr及びvegfr阻害剤であるビニル化合物
JP2018531218A6 (ja) Fgfr及びvegfr阻害剤であるビニル化合物
CN109071538B (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN110944989B (zh) 作为egfr激酶抑制剂的芳基磷氧化合物
CN107531695B (zh) Jak抑制剂
CN107531711B (zh) Janus激酶抑制剂
CN107614503B (zh) 稠环或三环芳基嘧啶化合物用作激酶抑制剂
CN110627784B (zh) 抗流感病毒嘧啶衍生物
JP7377798B2 (ja) c-MET/AXL阻害剤としてのウラシル系化合物
CN106459057A (zh) 作为PARP抑制剂的4H‑吡唑并[1,5‑α]苯并咪唑化合物的类似物
AU2006302135A1 (en) Kinase inhibitors
WO2020186220A1 (en) Compounds as inhibitors of macrophage migration inhibitory factor
KR102254660B1 (ko) A2a수용체 억제제로서의 축합 고리 유도체
AU2018223435A1 (en) Tri-cycle compound and applications thereof
WO2022199589A1 (zh) 嘧啶衍生物
CN107614498B (zh) 二氮杂-苯并荧蒽类化合物
CN109311908B (zh) 作为Akt抑制剂的二氢吡唑氮杂卓类化合物
CN107614501B (zh) 羟基嘌呤类化合物及其应用
CN109952290B (zh) Fgfr4抑制剂及其制备方法和应用
WO2023109918A1 (zh) 含氮杂环化合物、其制备方法及其用途
CN106065012A (zh) 咪唑类化合物
CN112851671A (zh) 一种4-取代的吡啶并[2,3-d]嘧啶-7-酮类化合物及其制备方法和应用
HK40004140A (en) Fgfr4 inhibitor and preparation method and use thereof
HK40004140B (en) Fgfr4 inhibitor and preparation method and use thereof
HK40018495B (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant after: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant before: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Applicant before: MEDSHINE DISCOVERY Inc.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20200628

Address after: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant after: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Address before: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant before: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant